Home
News
Create
Screeners
Insights
Aakaar Medical Technologies
74.
10
+0.80
(+1.09%)
Market Cap
₹105.02 Cr
PE Ratio
-
Industry
Consumer Goods
Buy
Sell
Company Performance:
1D
+1.09%
1M
+6.62%
6M
+2.21%
1Y
+4.00%
5Y
+4.00%
View Company Insights
Latest news about Aakaar Medical Technologies
Aakaar Medical Technologies revenue rises to ₹66.9 crore in FY26
3 days ago
Aakaar Medical Technologies Limited reported revenue of ₹66.9 crore for FY26, up from ₹61.6 crore in FY25. PAT increased to ₹6.6 crore, and EBITDA stood at ₹10.97 crore with a margin of 16.39%. The company's balance sheet expanded to ₹79.4 crore, driven by growth in shareholders' funds and cash reserves.
Aakaar Medical Technologies sets June 30 for 13th AGM
Jun 08, 2026
Aakaar Medical FY26 PAT rises 10% to ₹6.63 crore
Jun 06, 2026
Aakaar Medical FY26 PAT rises to ₹663.76 lakh
May 29, 2026
Aakaar Medical approves ESOP 2026, hikes share capital
May 26, 2026
More news about Aakaar Medical Technologies
22
May 26
Aakaar Medical fixes record date for 13th AGM
Aakaar Medical Technologies Limited scheduled its 13th AGM for June 30, 2026, via video conferencing. The record date for the notice is May 29, 2026, while the e-voting cut-off date is June 23, 2026.
16
May 26
Aakaar Medical Technologies to Set Up Aesthetics Device Manufacturing Facility in Pune
Aakaar Medical Technologies' Board of Directors approved the company's entry into Aesthetics Device manufacturing in their meeting on May 15, 2026. The company plans to lease a facility in Pune for contract manufacturing of Aesthetics Devices. The disclosure was made to the National Stock Exchange of India Limited under Regulation 30 of SEBI (LODR) Regulations, 2015. The arrangement involves no related party transactions, no special rights, and no share issuance or loan agreements.
16
May 26
Aakaar Medical Technologies Appoints M/s. NAM & ASSOCIATES as Secretarial Auditors for Five-Year Term
Aakaar Medical Technologies approved the appointment of M/s. NAM & ASSOCIATES as Secretarial Auditors at its Board meeting on May 15, 2026. The firm, holding Firm Registration No. S2016MH438800 and COP No. 17539, has been appointed for 5 consecutive years from FY2025-26 to FY2029-30, subject to shareholder approval at the ensuing Annual General Meeting. The appointment was made on the recommendation of the Audit Committee and is in compliance with SEBI Listing Regulations.
15
May 26
Aakaar Medical Technologies Updates Code of Fair Disclosure Under SEBI Insider Trading Regulations
Aakaar Medical Technologies Limited's Board approved the revision of its Code of Practices and Procedures for Fair Disclosure of UPSI on May 14, 2026, under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The policy, originally adopted on December 19, 2024 and now carrying Revision 01/2026, sets out principles for uniform UPSI dissemination, analyst interactions, compliance officer duties, and digital database maintenance. An accompanying Annexure A outlines the Policy for Determination of Legitimate Purposes for sharing UPSI. The revised code is publicly available on the company's official website.
10
May 26
Aakaar Medical Technologies Submits Structured Digital Database Compliance Certificate for Financial Year Ended March 31, 2026
Aakaar Medical Technologies Limited submitted its SDD compliance certificate for the financial year ended March 31, 2026, to the National Stock Exchange of India on May 09, 2026. Certified by Devendra V Deshpande of DVD & Associates, the certificate confirms all 52 required UPSI events were captured and no non-compliance was observed. A temporary technical issue in the SDD during February 2026 was resolved promptly, with no data loss or integrity concerns, and the matter was noted by the Audit Committee.
08
May 26
Aakaar Medical Technologies Schedules H2 & FY26 Earnings Call for May 15, 2026
Aakaar Medical Technologies Limited has scheduled its H2 & FY26 earnings conference call for May 15, 2026, at 4:30 PM IST, following the Board's approval of audited financial results for the year ended March 31, 2026. The call, organised by Go India Advisors, will feature Founder & MD Dilip Meswani, CEO Rahul Sawakhande, and CFO Rakesh Parekh, with pre-registration mandatory for dial-in access. The intimation was filed under SEBI Regulation 30 and submitted to NSE on May 07, 2026.
Aakaar Medical Technologies
74.
10
+
0.
80
(+
1.
09
%)
1 Year Returns:
+4.00%
Industry Peers
Godrej Consumer Products
1,034.60
(+
1.
38
%)
Dabur India
423.90
(-
0.
05
%)
Colgate Palmolive
1,993.00
(+
1.
41
%)
P&G Hygiene and Health Care
9,020.50
(+
0.
46
%)
Gillette
7,719.00
(-
0.
95
%)
Cupid
182.61
(+
1.
74
%)
Emami
396.95
(-
1.
72
%)
Mamaearth
417.70
(+
0.
42
%)
Bajaj Consumer Care
578.45
(-
1.
97
%)
Anondita Medicare
1,177.15
(-
4.
54
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar